论文部分内容阅读
目的观察普米克气雾剂干预能否减少婴幼儿喘息性疾病的反复发作。方法选择2008年6月—2009年5月,首次发作的婴幼儿喘息性疾病60例,随机分为治疗组(30例)和对照组(30例)。治疗组,在急性喘息控制后给予普米克气雾剂吸入干预治疗70d,并观察治疗结束后1年患儿反复喘息发生的情况。对照组未给予治疗。结果在1年随访中,治疗组喘息复发5例,共13人次,平均1年发作0.43次;对照组喘息复发17例,共76人次,平均1年发作2.53次。治疗组复发次数明显减少,两组比较差异有统计学意义(P<0.05)。结论普米剂克气雾剂干预可以减少1年内婴幼儿喘息性疾病的发作次数,简单实用,值得推广。
Objective To observe whether Pulmicort aerosol intervention can reduce recurrent episodes of asthmatic wheezing in infants and young children. Methods Sixty infants with wheezing infants who were first attacked from June 2008 to May 2009 were randomly divided into treatment group (30 cases) and control group (30 cases). In the treatment group, Pulmicort aerosol inhalation was given for 70 days after acute asthma control, and repeated wheezing was observed 1 year after the end of treatment. The control group did not receive treatment. Results In the one-year follow-up, the treatment group had 5 cases of wheezing relapse, with a total of 13 visits, with an average of 0.43 episodes per 1 year. In the control group, wheeze relapsed in 17 cases, with a total of 76 visits, with an average of 2.53 episodes per year. Treatment group significantly reduced the number of relapse, the difference between the two groups was statistically significant (P <0.05). Conclusion Pulmicort aerosol intervention can reduce the number of infantile asthma attacks within 1 year, simple and practical, it is worth promoting.